A share price of Biocryst Pharmaceuticals Inc. [BCRX] is currently trading at $5.36, up 5.72%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The BCRX shares have gain 4.28% over the last week, with a monthly amount drifted -9.46%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 5, March 2024, BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4). In a post published today on Yahoo Finance, BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted three newly-hired employees stock options to purchase an aggregate of 16,050 shares, and restricted stock units (RSUs) covering an aggregate of 11,300 shares, of BioCryst common stock. The options and RSUs were granted as of February 29, 2024, as inducements material to each employee entering into employment with BioCryst. The options and RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
From an analyst’s perspective:
Previously, RBC Capital Mkts upgraded its rating to Outperform on September 18, 2023, and elevated its price target to $10. On August 04, 2023, upgrade upgraded it’s rating to Buy but maintained its price target of $11 on the stock. BofA Securities upgraded its rating to a Buy but stick to its price target of $10 on July 13, 2023. Needham upgraded its rating to a Buy but $14 remained the price target by the analyst firm on February 22, 2023. Evercore ISI upgraded its rating to Outperform for this stock on November 02, 2022, and upped its price target to $16. In a note dated August 05, 2022, Oppenheimer downgraded an Perform rating on this stock.
Biocryst Pharmaceuticals Inc. experienced fluctuations in its stock price throughout the past year between $4.82 and $9.06. Currently, Wall Street analysts expect the stock to reach $19 within the next 12 months. Biocryst Pharmaceuticals Inc. [NASDAQ: BCRX] shares were valued at $5.36 at the most recent close of the market. An investor can expect a potential return of 254.48% based on the average BCRX price forecast.
Analyzing the BCRX fundamentals
Trailing Twelve Months sales for Biocryst Pharmaceuticals Inc. [NASDAQ:BCRX] were 331.41M which represents 17.42% growth. Gross Profit Margin for this corporation currently stands at 0.98% with Operating Profit Margin at -0.31%, Pretax Profit Margin comes in at -0.68%, and Net Profit Margin reading is -0.68%. To continue investigating profitability, this company’s Return on Assets is posted at -0.44, Equity is 0.18 and Total Capital is -0.28. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -1.84.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 5.13 points at the first support level, and at 4.89 for the second support level. However, for the 1st resistance point, the stock is sitting at 5.51, and for the 2nd resistance point, it is at 5.66.
Biocryst Pharmaceuticals Inc. [BCRX] reported earnings per share of -$0.31 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.24/share, meaning a difference of -$0.07 and a surprise factor of -29.20%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were -$0.19 per share as compared to estimates of -$0.23 per share, a difference of $0.04 representing a surprise of 17.40%.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Biocryst Pharmaceuticals Inc. [NASDAQ:BCRX] is 3.31. Further, the Quick Ratio stands at 3.12, while the Cash Ratio is 0.75. Considering the valuation of this stock, the price to sales ratio is 3.33.
Transactions by insiders
Recent insider trading involved SANDERS MACHELLE, Director, that happened on Jun 15 ’23 when 4000.0 shares were sold. Director, Hutson Nancy J completed a deal on Jun 14 ’23 to sell 12866.0 shares. Meanwhile, Chief R&D Officer Thackray Helen M. sold 7000.0 shares on Apr 03 ’23.
